Tresiba FDA Approval History
Tresiba (insulin degludec) is a long-acting basal insulin analogue indicated to improve glycemic control in patients one year of age and older with diabetes mellitus.
Development Timeline for Tresiba
|Dec 19, 2016||Novo Nordisk Receives FDA Approval of Tresiba (insulin degludec) for Use in Children and Adolescents With Diabetes|
|Sep 25, 2015||FDA Approves Tresiba (insulin degludec) for Diabetes Mellitus|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.